Elevated SLC6A6 expression drives tumorigenesis and affects clinical outcomes in gastric cancer.

CONCLUSION: SLC6A6 may be a potential prognostic marker and therapeutic target. Hypomethylation contributes to SLC6A6 upregulation in gastric cancer. PMID: 30767502 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research